Chase Investment Counsel Corp Increases Stake in HealthEquity, Inc. (NASDAQ:HQY)

Chase Investment Counsel Corp increased its holdings in shares of HealthEquity, Inc. (NASDAQ:HQY) by 25.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,420 shares of the company’s stock after purchasing an additional 1,497 shares during the quarter. Chase Investment Counsel Corp’s holdings in HealthEquity were worth $711,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Versor Investments LP purchased a new stake in HealthEquity during the fourth quarter worth approximately $873,000. Proficio Capital Partners LLC purchased a new stake in HealthEquity during the fourth quarter worth approximately $39,000. Oppenheimer Asset Management Inc. lifted its stake in HealthEquity by 2.1% during the fourth quarter. Oppenheimer Asset Management Inc. now owns 70,592 shares of the company’s stock worth $6,773,000 after purchasing an additional 1,453 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its stake in HealthEquity by 0.6% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 17,776 shares of the company’s stock worth $1,706,000 after purchasing an additional 100 shares during the last quarter. Finally, First Horizon Advisors Inc. lifted its stake in HealthEquity by 50.7% during the fourth quarter. First Horizon Advisors Inc. now owns 1,115 shares of the company’s stock worth $107,000 after purchasing an additional 375 shares during the last quarter. Hedge funds and other institutional investors own 99.55% of the company’s stock.

HealthEquity Stock Up 2.6 %

HealthEquity stock opened at $109.76 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.20 and a quick ratio of 3.20. HealthEquity, Inc. has a 1-year low of $65.01 and a 1-year high of $115.59. The company has a market cap of $9.51 billion, a PE ratio of 100.70, a price-to-earnings-growth ratio of 1.60 and a beta of 0.55. The stock’s 50 day moving average price is $104.84 and its 200 day moving average price is $93.08.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings results on Monday, December 9th. The company reported $0.59 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.12). HealthEquity had a net margin of 8.41% and a return on equity of 9.70%. During the same period in the previous year, the company earned $0.40 earnings per share. On average, sell-side analysts predict that HealthEquity, Inc. will post 2.32 EPS for the current fiscal year.

Insider Activity at HealthEquity

In other HealthEquity news, Director Robert W. Selander sold 8,250 shares of the business’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $101.56, for a total transaction of $837,870.00. Following the sale, the director now directly owns 66,469 shares in the company, valued at approximately $6,750,591.64. The trade was a 11.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Stuart B. Parker sold 25,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $96.72, for a total value of $2,418,000.00. Following the sale, the director now owns 19,061 shares in the company, valued at approximately $1,843,579.92. The trade was a 56.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 39,000 shares of company stock worth $3,895,788 over the last three months. 2.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

HQY has been the subject of several recent analyst reports. Bank of America boosted their target price on HealthEquity from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. JMP Securities lifted their price target on HealthEquity from $105.00 to $107.00 and gave the stock a “market outperform” rating in a research report on Tuesday, December 10th. Raymond James lifted their price target on HealthEquity from $105.00 to $120.00 and gave the stock an “outperform” rating in a research report on Tuesday. BTIG Research lifted their price target on HealthEquity from $110.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, November 14th. Finally, Royal Bank of Canada boosted their target price on HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, HealthEquity has a consensus rating of “Moderate Buy” and an average price target of $113.54.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.